GSK-Spero’s oral antibiotic tebipenem pivoxil hydrobromide, branded Utebzi, won US FDA approval for complicated urinary tract infections, including pyelonephritis. The approval arrives after the FDA issued a complete response letter four years earlier, with the agency now greenlighting the drug based on Phase III data demonstrating noninferiority versus IV imipenem-cilastatin. Utebzi is expected to be available by the end of 2026. Under a $600 million license deal signed in September 2022, GSK gained global rights except for Japan and certain Asian countries retained by the original developer, Meiji Seika Pharma, while Spero licensed rights from Meiji in 2017. The approval highlights continued interest in oral alternatives to IV carbapenem-class treatment for resistant and complicated infections, where outpatient suitability and reduced infusion burden remain major endpoints. For the antibiotic category, the decision expands the set of non-fully parenteral options and reinforces the viability of oral pivots in difficult-to-treat indications.